This British Society for Microbial Technology (BSMT) virtual conference, held in conjunction with media partner Pathology in Practice, on 11–14 May, will be sponsored by 22 companies.
IONTAS and FairJourney Biologics have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Beckman Coulter today has expanded claims for its CE-marked Access Interleukin-6 (IL-6) assay, an in vitro diagnostic test for the quantitative determination of IL-6 levels in human serum and plasma.
Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, has announced a commercial partnership with Mologic, a developer and manufacturer of lateral-flow and rapid diagnostic tests.
Additions to the programme and sponsors for this important British Society for Microbial Technology (BSMT) virtual conference, which will be held on 11–14 May, have now been released. See the following for the latest details…
The British Society for Microbial Technology (BSMT) will hold a virtual conference entitled ‘COVID-19 – The Infection Challenging the World' over four days in May. Click on this story for current details of the programme and commercial support.
Avacta Group has announced that the AffiDX SARS-CoV-2 rapid antigen lateral-flow test detects the dominant new variants of the coronavirus, known as the B117 (Kent), variant, and the D614G variant, as well as the original strain.
Roche Diagnostics has launched a rapid antigen nasal test in the UK, with millions of kits available immediately to help businesses and organisations looking to reopen as lockdown restrictions are lifted.
Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel.
The SARS-CoV-2 pandemic has resulted in a challenging work environment. This has made the development and commercialisation of vaccines, treatments and critically needed PCR-based and serological diagnostics especially challenging.
Randox has processed its 10-millionth sample for the UK’s COVID-19 National Testing Programme, making it the first Pillar 2 testing laboratory to achieve this milestone, having invested £85 million since March 2020 in facilities and equipment.
Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, which show excellent performance in identifying patients with an infectious viral load and no false positive results.
South African scientists warn of grave danger that disinfectant use against SARS-CoV-2 could be helping bacteria to become resistant to disinfectants.
The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2 and medicine’s response to cases of severe COVID-19 disease.
Avacta Group and Mologic have entered a partnership to market Avacta’s AffiDX SARS-CoV-2 lateral-flow rapid antigen test. Avacta will also support antigen testing in low- and middle-income countries by providing access to Avacta’s spike antigen test.
The British Society for Microbial Technology (BSMT) will hold a virtual conference entitled ‘COVID-19 – The Infection Challenging the World' over four days in May. Click on this story for an update on the conference programme and commercial support.
Avacta Group has entered into a collaboration agreement with Bruker to evaluate the Affimer-based, bead-assisted mass spectrometry (BAMS) SARS-CoV-2 assay, developed with Adeptrix.
The British Society for Microbial Technology (BSMT) is organising a virtual conference entitled ‘COVID-19 – The Infection that Challenged the World: Is Necessity the Mother of Invention?’
Randox Laboratories has launched its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both the spike receptor binding domain (RBD) and nucleocapsid protein (NP).